Nektar Therapeutics reported $57.71M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
Agios Pharmaceuticals USD 77.59M 7.37M Sep/2026
ALKERMES USD 651.93M 10.16M Sep/2026
Alterity Therapeutics Limited AUD 1.73M 2.77M Dec/2025
Amgen USD 23.23B 2.27B Sep/2026
Baxter International USD 3.81B 218M Sep/2026
BioCryst Pharmaceuticals USD 195.83M 13.02M Sep/2026
Biogen USD 3.9B 18.7M Sep/2026
Bristol-Myers Squibb USD 18.75B 94M Sep/2026
Cara Therapeutics USD 8.08M 3.18M Sep/2026
Cipla INR 69.77B 366.6M Sep/2026
Dr.Reddys Laboratories INR 154.3B 3.04B Sep/2026
Eisai JPY 371.5B 22.14B Sep/2026
Eli Lilly USD 47B 745M Sep/2026
Exelixis USD 411.88M 49.95M Sep/2026
Gilead Sciences USD 12B 982M Sep/2026
GlaxoSmithKline GBP 20.72B 814M Sep/2026
Grifols EUR 2.37B 156.97M Dec/2025
Halozyme Therapeutics USD 476.09M 131.65M Sep/2026
Incyte USD 1.44B 125.72M Sep/2026
Ionis Pharmaceuticals USD 435.29M 119.65M Sep/2026
Ironwood Pharmaceuticals USD 34.73M 1.88M Sep/2026
Karyopharm Therapeutics USD 117.3M 25.24M Mar/2026
MacroGenics USD 107.23M 1.58M Sep/2026
Merck USD 28.8B 1.07B Sep/2026
Nektar Therapeutics USD 57.71M 4.17M Mar/2026
Neurocrine Biosciences USD 984.6M 110.1M Sep/2026
Novartis USD 32.52B 777M Sep/2026
Pfizer USD 31.73B 920M Sep/2026
Roche Holding CHF 28.85B 846M Jun/2026
Sarepta Therapeutics USD 656.35M 153.44M Sep/2026
Takeda JPY 2.6T 161B Sep/2026
Teva Pharmaceutical Industries USD 15.42B 221M Sep/2026
Xencor USD 76.27M 5.6M Sep/2026